This is a preview of subscription content, log in via an institution to check access.
References
Yang H, et al. Cost-Effectiveness of Tisagenlecleucel for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma : a Canadian Societal Perspective. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN177, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85193?pdfid=58705
Yang H, et al. Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: a Canadian Societal Perspective. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN170, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/86304?pdfid=58627
Hollmann S, et al. Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN72, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85168?pdfid=58708
Hollmann S, et al. Budget Impact Analysis of Tisagenlecleucel for the Treatment of Paediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in England. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN68, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85189?pdfid=58707
Rights and permissions
About this article
Cite this article
Cost effectiveness and budget impact of tisagenlecleucel. PharmacoEcon Outcomes News 817, 12 (2018). https://doi.org/10.1007/s40274-018-5469-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-5469-y